Additionally, breast cancer patients with high Mortalin expression had decreased DFS and OS compared to those with low Mortalin expression in either Early stage cases (P = 0.043, P = 0.042 respectively) or late-stage cases (P = 0.008, P = 0.010 respectively) (Fig. 5). This evidence concerns the gene HSPA9 and breast cancer.